Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction
- 7 July 2015
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 199, 53-62
Abstract
No abstract availableKeywords
Funding Information
- Korean Health Technology R&D Project (HI13C1527)
This publication has 45 references indexed in Scilit:
- One-Year Clinical Outcomes among Patients with Metabolic Syndrome and Acute Myocardial InfarctionKorean Circulation Journal, 2013
- Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary StentsCirculation, 2012
- Stent Thrombosis With Everolimus-Eluting StentsCirculation: Cardiovascular Interventions, 2012
- A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World PatientsJACC, 2012
- Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or DiabetesJACC: Cardiovascular Imaging, 2012
- Impact of Polymer Formulations on Neointimal Proliferation After Zotarolimus-Eluting Stent With Different PolymersCirculation: Cardiovascular Interventions, 2011
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsNew England Journal of Medicine, 2010
- Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in KoreaKorean Circulation Journal, 2009
- The importance of left ventricular function for long-term outcome after primary percutaneous coronary interventionBMC Cardiovascular Disorders, 2008
- Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysmEuropean Heart Journal, 2007